Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2016

Open Access 01-12-2016 | Clinical Guides in Oncology

SEOM Clinical Guideline in ovarian cancer (2016)

Authors: A. Santaballa, P. Barretina, A. Casado, Y. García, A. González-Martín, E. Guerra, N. Laínez, J. Martinez, A. Redondo, I. Romero

Published in: Clinical and Translational Oncology | Issue 12/2016

Login to get access

Abstract

Despite remarkable advances in the knowledge of molecular biology and treatment, ovarian cancer (OC) is the first cause of death due to gynecological cancer and the fifth cause of death for cancer in women in Spain. The aim of this guideline is to summarize the current evidence and to give evidence-based recommendations for clinical practice.
Literature
1.
Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;5(11):668–79 (PubMed PMID: 26493647. Pubmed Central PMCID: 4892184).CrossRef
2.
Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumors of the female reproductive organs. 4th ed, vol 6. WHO Press; 2014.
3.
Kobel M, Rahimi K, Rambau PF, Naugler C, Le Page C, Meunier L, et al. An immunohistochemical algorithm for ovarian carcinoma typing. Int J Gynecol Pathol. 2016;35(5):430–41 (PubMed PMID: 26974996. Pubmed Central PMCID: 4978603).CrossRefPubMedPubMedCentral
4.
Singh N, Gilks CB, Hirschowitz L, Kehoe S, McNeish IA, Miller D, et al. Primary site assignment in tubo-ovarian high-grade serous carcinoma: consensus statement on unifying practice worldwide. Gynecol Oncol. 2016;141(2):195–8 (PubMed PMID: 26827965).CrossRefPubMed
5.
Trimbos B, Timmers P, Pecorelli S, Coens C, Ven K, van der Burg M, et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Ntl Cancer Inst. 2010;102(13):982–7 (PubMed PMID: 20445161. Pubmed Central PMCID: 2911043).CrossRef
6.
Koo YJ, Kim JE, Kim YH, Hahn HS, Lee IH, Kim TJ, et al. Comparison of laparoscopy and laparotomy for the management of early-stage ovarian cancer: surgical and oncological outcomes. J Gynecol Oncol. 2014;25(2):111–7 (PubMed PMID: 24761214. Pubmed Central PMCID: 3996260).CrossRefPubMedPubMedCentral
7.
Bellia A, Vitale SG, Lagana AS, Cannone F, Houvenaeghel G, Rua S, et al. Feasibility and surgical outcomes of conventional and robot-assisted laparoscopy for early-stage ovarian cancer: a retrospective, multicenter analysis. Arch Gynecol Obstet. 2016;294(3):615–22 (PubMed PMID: 27040423).CrossRefPubMed
8.
Zhou J, Shan G, Chen Y. The effect of lymphadenectomy on survival and recurrence in patients with ovarian cancer: a systematic review and meta-analysis. Jpn J Clin Oncol. 2016;46(8):718–26 (PubMed PMID: 27272175).CrossRefPubMed
9.
Stuart GC, Kitchener H, Bacon M, du Bois A, Friedlander M, Ledermann J, et al. Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2010;21(4):750–5 (PubMed PMID: 21543936).CrossRef
10.
du Bois A, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I, Pfisterer J, et al. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol. 2010;28(10):1733–9 (PubMed PMID: 20194855).CrossRefPubMed
11.
Harter P, Hahmann M, Lueck HJ, Poelcher M, Wimberger P, Ortmann O, et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009;16(5):1324–30 (PubMed PMID: 19225844).CrossRefPubMed
12.
Chiva LM, Gonzalez-Martin A. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer. Gynecol Oncol. 2015;136(1):130–5.CrossRefPubMed
13.
Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53 (PubMed PMID: 20818904).CrossRefPubMed
14.
Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249–57 (PubMed PMID: 26002111).CrossRefPubMed
15.
Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003;95(2):105–12 (PubMed PMID: 12529343).CrossRefPubMed
16.
Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol. 2011;29(27):3628–35 (d PubMed PMID: 21844495).CrossRefPubMed
17.
Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14(10):1020–6 PubMed PMID: 23948349.CrossRefPubMed
18.
Gonzalez-Martin A, Bover I, Del Campo JM, Redondo A, Vidal L. Spanish Society for Medical Oncology. SEOM guideline in ovarian cancer 2014. Clin Transl Oncol. 2014;16(12):1067–71 (PubMed PMID: 25351169. Pubmed Central PMCID: 4239783).CrossRefPubMedPubMedCentral
19.
Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015;33(13):1460–6 (PubMed PMID: 25800756. Pubmed Central PMCID: 4404424).CrossRefPubMedPubMedCentral
20.
Oaknin A, Roda D, Gonzalez-Martin A, Chiva L, Garcia-Donas J, de Juan A, et al. Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study. Int J Gynecol Cancer. 2011;21(6):1048–55 PubMed PMID: 21738038.CrossRefPubMed
21.
Aravantinos G, Pectasides D. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review. J Ovar Res. 2014;7:57 (PubMed PMID: 24864163. Pubmed Central PMCID: 4033616).CrossRef
22.
Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON-7): overall survival results of a phase 3 randomsed trial. Lancet oncol. 2015;16:928–36.CrossRefPubMedPubMedCentral
23.
Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–45 (PubMed PMID: 22529265. Pubmed Central PMCID: 3646321).CrossRefPubMedPubMedCentral
24.
Colemana RL, Bradya MF, Herzogc TJ, Sabbatinid P, Armstronge DK, Walker JL, et al. A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer. Presented at: Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer 2015; March 28–31, 2015; Chicago, IL. Abstract 3 (late breaking).
25.
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852–61 PubMed PMID: 24882434.CrossRefPubMed
26.
Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol. 2011;22(1):39–48 (PubMed PMID: 20643862. Pubmed Central PMCID: 3003616).CrossRefPubMed
27.
Pignata S, Scambia G, Raspagliesi F, Murgia V, Pisano C, Salutari V, et al. The MITO8 phase III international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum-based chemotherapy: A collaboration of MITO, MANGO, AGO, BGOG, ENGOT, and GCIG. J Clin Oncol. 2016;34(suppl; abstr 5505).
28.
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8 (PubMed PMID: 24637997).CrossRefPubMed
Metadata
Title
SEOM Clinical Guideline in ovarian cancer (2016)
Authors
A. Santaballa
P. Barretina
A. Casado
Y. García
A. González-Martín
E. Guerra
N. Laínez
J. Martinez
A. Redondo
I. Romero
Publication date
01-12-2016
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 12/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1588-8

Other articles of this Issue 12/2016

Clinical and Translational Oncology 12/2016 Go to the issue

Clinical Guides in Oncology

SEOM Clinical Guideline of localized rectal cancer (2016)

Clinical Guides in Oncology

SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016)

Editorial

SEOM guidelines 2016: an update

Clinical Guides in Oncology

SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016)

Clinical Guides in Oncology

SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)

Clinical Guides in Oncology

SEOM clinical guidelines for the management of germ cell testicular cancer (2016)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits